Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study
- PMID: 39344920
- DOI: 10.1093/eurheartj/ehae639
Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study
Abstract
Background and aims: While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort.
Methods: Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders.
Results: For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1-2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06-1.28) for dose one and HR 1.22 (95% CI 1.10-1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05-1.23), mainly in elderly] but not for stroke.
Conclusions: Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.
Keywords: COVID-19 vaccine; Cardiovascular diseases; Survival analysis.
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
Similar articles
-
SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents.JAMA Cardiol. 2022 Jun 1;7(6):600-612. doi: 10.1001/jamacardio.2022.0583. JAMA Cardiol. 2022. PMID: 35442390 Free PMC article.
-
Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.PLoS Med. 2023 Jun 7;20(6):e1004245. doi: 10.1371/journal.pmed.1004245. eCollection 2023 Jun. PLoS Med. 2023. PMID: 37285378 Free PMC article.
-
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807. Immun Inflamm Dis. 2023. PMID: 36988252 Free PMC article. Review.
-
Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study.J Microbiol Immunol Infect. 2023 Jun;56(3):558-565. doi: 10.1016/j.jmii.2023.01.016. Epub 2023 Feb 8. J Microbiol Immunol Infect. 2023. PMID: 36804307 Free PMC article.
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
Grants and funding
LinkOut - more resources
Full Text Sources
